Common adverse events (AEs) associated with inotuzumab ozogamicin include abdominal pain, anemia, fatigue, febrile neutropenia, headache, hemorrhage, hyperbilirubinemia, infection, leukopenia, liver damage, nausea, neutropenia, pyrexia, and thrombocytopenia. (cancernetwork.com)
Inotuzumab ozogamicin includes a boxed warning due to the risk of severe hepatotoxicity, including sinusoidal obstruction syndrome or veno - occlusive disease (VOD). (cancernetwork.com)
Inotuzumab ozogamicin may cause harm to a fetus or newborn; as such, women who are pregnant or breastfeeding should not take the drug. (cancernetwork.com)